These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 4935027)

  • 1. Metabolism and clinical assessment of L-dopa in parkinsonism.
    Ericsson AD; McCann D; Sharpless N; Reveno W
    Neurology; 1970 Apr; 20(4):402. PubMed ID: 4935027
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of Parkinsonism with L-dopa--with special reference to clinical effects, side effects and urinary metabolites of catecholamines].
    Uono M; Tanabe H; Yano Y; Nakao K
    No To Shinkei; 1970 Sep; 22(9):1091-101. PubMed ID: 5536082
    [No Abstract]   [Full Text] [Related]  

  • 3. [Use of L-DOPA in the therapy of parkinsonism].
    D'Andrea F; De Divitiis E; Signorelli CD; Cerillo A; Tedeschi G
    Rass Int Clin Ter; 1971 Feb; 51(4):193-221. PubMed ID: 4930734
    [No Abstract]   [Full Text] [Related]  

  • 4. Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism.
    Chase TN
    Neurology; 1970 Dec; 20(12):Suppl:36-40. PubMed ID: 5312403
    [No Abstract]   [Full Text] [Related]  

  • 5. L-Dopa (L-3,4-dihydroxyphenylanine)--its clinical effects in parkinsonism.
    Yahr MD; Duvoisin RC; Hoehn MM; Schear MJ; Barrett RE
    Trans Am Neurol Assoc; 1968; 93():56-63. PubMed ID: 4885744
    [No Abstract]   [Full Text] [Related]  

  • 6. Serial determinations of homovanillinic acid in the cerebrospinal fluid of Parkinson patients treated with L-dopa.
    Bertler A; Jeppsson PG; Nordgren L; Rosengren E
    Acta Neurol Scand; 1971; 47(4):393-402. PubMed ID: 4941731
    [No Abstract]   [Full Text] [Related]  

  • 7. L-dopa and amantadine in the therapy of parkinsonism.
    Weeth JB; Shealy CN; Mercier DA
    Wis Med J; 1969 Nov; 68(11):325-8. PubMed ID: 4901055
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of Parkinson's disease with L-DOPA and decarboxylase inhibitor.
    Rinne UK; Sonninen V; Sirtola T
    Z Neurol; 1972; 202(1):1-20. PubMed ID: 4114458
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical and cerebrospinal fluid changes in parkinsonian patients treated with L-3,4-dihydroxyphenylalanine (L-dopa).
    Sharpless NS; Ericsson AD; McCann DS
    Neurology; 1971 May; 21(5):540-9. PubMed ID: 5104098
    [No Abstract]   [Full Text] [Related]  

  • 10. L-Dopa treatment in Parkinson's Disease.
    Rinne UK; Sonninen V; Siirtola T
    Eur Neurol; 1970; 4(6):348-69. PubMed ID: 4932969
    [No Abstract]   [Full Text] [Related]  

  • 11. Biochemical investigations in Parkinsonism. A study of the metabolites of the biogenic amines in the lumbar CSF.
    Pullar IA; Dowson JH; Ahmed R; Chow R; Gillingham FJ
    Confin Neurol; 1972; 34(2):143-8. PubMed ID: 4666057
    [No Abstract]   [Full Text] [Related]  

  • 12. [L-dopa and parkinsonism. A preliminary report].
    Pakkenberg H
    Ugeskr Laeger; 1969 May; 131(22):959-60. PubMed ID: 5793628
    [No Abstract]   [Full Text] [Related]  

  • 13. Biochemical investigations in Parkinsonism. A study of the metabolites of the biogenic amines in the lumbar CSF.
    Pullar IA; Dowson JH; Ahmed R; Chow R; Gillingham FJ
    Confin Neurol; 1972; 34(1):143-8. PubMed ID: 5084388
    [No Abstract]   [Full Text] [Related]  

  • 14. [Clinical experience with L-DOPA in the treatment of parkinsonism].
    Chiba T
    No To Shinkei; 1970 Dec; 22(12):1399-405. PubMed ID: 5536833
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clinical effect of L-DOPA and electromyographic study of Parkinsonism].
    Sato G; Ito H; Handa Y; Takahashi I; Iijima K
    No To Shinkei; 1971 Mar; 23(3):325-32. PubMed ID: 5107821
    [No Abstract]   [Full Text] [Related]  

  • 16. Mood changes during l-dopa therapy.
    Anumonye A
    J Med Soc N J; 1972 Feb; 69(2):139-43. PubMed ID: 4550284
    [No Abstract]   [Full Text] [Related]  

  • 17. [Evaluation of L-DOPA in Parkinsonism with special reference to the study by double-blind method].
    Okajima T; Kubota A; Nakahara N; Takeda S; Shimomura K
    Naika; 1972; 29(2):335-43. PubMed ID: 4552443
    [No Abstract]   [Full Text] [Related]  

  • 18. [Effects of L-dopa and stereotaxic surgery in Parkinsonism].
    Sugita K; Mutsuga N; Takaoka Y; Takeda A
    No To Shinkei; 1970 Sep; 22(9):1103-8. PubMed ID: 4918927
    [No Abstract]   [Full Text] [Related]  

  • 19. [The effect of alpha-DOPA on the dynamics of urinary excretion of DOPA, catecholamines and their metabolites in healthy subjects and in patients with parkinsonism].
    Matlina ESh; Kandel' EI; Vasil'ev VN; Iadgarov IS; Bol'shakova TD
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(2):205-9. PubMed ID: 4743269
    [No Abstract]   [Full Text] [Related]  

  • 20. [Therapeutic effects of L-dopa and trihexyphenidyl in Parkinson's disease--an examination by a double blind method].
    Hirayama K; Uono M; Nakanishi T; Kato N; Nagao Y
    Shinkei Kenkyu No Shimpo; 1971; 15(1):267-85. PubMed ID: 4937721
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.